title: Ten years of experience with the pneumococcal conjugate 7-valent vaccine in children.
abstract: In children, pneumococcus became the predominant infectious agent, after the routine use of the Hib conjugate vaccine dramatically decreased Haemophilus Influenzae type b prevalence. The incidence of invasive pneumococcal infections (IPI) and of non-invasive infections due to vaccine serotypes (VS) decreased by 80% in Europe along with a 30-40% decrease in the global incidence of IPI in this age group, after the implementation of Prevenar 7(®) routine immunization in children below 2 years of age. The decrease of IPI due to VS in other age groups was an indirect benefit. The moderate increase of non-vaccinal serotype IPI incidence did not impede the benefit of the overall program. Serotype 19A was the most frequent and carried resistance to antibiotics. Prevenar 13(®), a second-generation vaccine with six new serotypes, replaced Prevenar 7(®) in most countries after 2010, with available evidence of its effectiveness (United Kingdom, US, France).
authors.affiliation: University Paris-VII, place Jussieu-Paris, 75005 Paris, France. cweilolivier@gmail.com
authors.forename: C
authors.initials: C
authors.lastname: Weil Olivier
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D000907:Antibodies, Bacterial / Q000097:blood; D001315:Australia / Q000453:epidemiology; D002353:Carrier State / Q000453:epidemiology / Q000382:microbiology; D002675:Child, Preschool; D024901:Drug Resistance, Multiple, Bacterial; D005060:Europe / Q000453:epidemiology; D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D006760:Hospitalization / Q000706:statistics & numerical data; D006801:Humans; D015994:Incidence; D007223:Infant; D007231:Infant, Newborn; D007557:Israel / Q000453:epidemiology; D009305:Nasopharynx / Q000382:microbiology; D009656:North America / Q000453:epidemiology; D011008:Pneumococcal Infections / Q000188:drug therapy / Q000453:epidemiology / Q000517:prevention & control*; D022242:Pneumococcal Vaccines; D012189:Retrospective Studies; D012703:Serotyping; D013296:Streptococcus pneumoniae / Q000145:classification / Q000187:drug effects / Q000276:immunology / Q000302:isolation & purification; D014611:Vaccination; D015164:Vaccines, Inactivated
chemical_list: C538862:13-valent pneumococcal vaccine; D000900:Anti-Bacterial Agents; D000907:Antibodies, Bacterial; D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D022242:Pneumococcal Vaccines; D015164:Vaccines, Inactivated
keywords: Community-acquired pneumococcal pneumonia; Maladies invasives à pneumocoque; Pneumococcal conjugate vaccine 7-valent; Pneumococcal invasive diseases; Pneumonies à pneumocoques; Vaccin conjugué pneumococcique 7-valent